Xihong Biopharma’s Injectable Sodium Hyaluronate Composite Solution Receives Class III Approval from China’s NMPA
Jiangsu Xihong Biopharma Co., Ltd. (“Xihong Biopharma”) today announced that its Injectable Sodium Hyaluronate Composite Solution (the “Product”), developed and manufactured by Xihong Biopharma, has officially received Class III medical device registration approval from the National Medical Products Administration (NMPA) of China on December 10, 2025 (Registration No.: 国械注准20253132504).
This approval marks another key milestone in Xihong Biopharma’s R&D and technology translation efforts, signifying the company’s continued advancement in offering a differentiated product portfolio and taking a stronger step forward in promoting compliant, safe, and effective regenerative medical solutions.
The approved product is designed for Skin Booster, temporarily improving skin dryness and dullness in adults. Approved under China’s Class III medical device framework, it reflects regulatory recognition of its safety and clinical efficacy. As a sodium hyaluronate-based compound, it delivers effective hydration and nourishment, meeting growing market demand for routine skin maintenance and visible skin-quality improvement.
Mr. Zhang Tianming, General Manager of Xihong Biopharma, stated:
"This approval marks a key milestone for Xihong Biopharma and our parent company, Oriental Beauty Valley, in delivering innovative, high-quality products to the market. We remain committed to leveraging our R&D expertise and the highest compliance standards to bring more rigorously validated regenerative solutions to market efficiently."
The Injectable Sodium Hyaluronate Composite Solution has also officially entered international markets. We warmly invite partners worldwide to explore collaboration opportunities and expand mutually beneficial business. Stay tuned for more upcoming product approvals—Xihong Biopharma will continue to empower global medical aesthetics professionals with high-quality solutions, supporting deeper market engagement and new growth opportunities.
About Xihong Biopharma
Established in 2016, we provide end-to-end solutions for regenerative medicine devices—from R&D to commercial manufacturing—through ODM, CDMO, technology transfer, and joint ventures. Our main products include PLLA, CaHA, PCL, and PMMA-based injectable fillers for aesthetic and tissue regeneration applications
